---
title: Conditional Independence Tests for Constraint-Based Causal Discovery: A Survey
url: http://arxiv.org/abs/2608.11156v1
type: paper-summary
date: 2026-08-11
source_paper: 2026-08-11_17-13-52Z_ConditionalIndependenceTestsforConstraint_BasedCau.md
generated_at: 2026-08-11 22:20
model: nvidia/nemotron-3-nano-4b
---

## Summary
The paper surveys conditional independence tests for constraint-based causal discovery, grouping methods into six families and analyzing their assumptions, robustness, and scalability in high-dimensional biomedical settings. It links test-level properties such as power decay with conditioning set size to errors in skeleton recovery and v-structure orientation. The authors compare adoption across R and Python libraries and highlight open challenges like mixed-type CI testing without discretization.

## Key Takeaways
- Conditional independence tests are the statistical engine of algorithms like PC and FCI, but their performance degrades as conditioning set size grows, leading to reduced power and asymmetric type I/II errors that affect graph reconstruction. 
- The survey identifies robustness layers for each CI family, showing when tests reflect the data-generating distribution versus failing due to violations such as v-structures or discretization artifacts. 
- Open challenges include performing mixed-type CI testing without discretization, controlling small-sample error rates, and improving scalability of CI-testing across high-dimensional biomedical datasets.

## Context
In AI and causal discovery, accurate inference from observational data is essential for interpreting complex biological networks. This survey underscores that the choice of conditional independence test can profoundly influence the reliability of inferred causal graphs, especially when dealing with mixed variable types common in medical research.

## Implications
Practitioners must select CI methods that balance robustness to v-structures and scalability for large datasets. Addressing these challenges will improve trust in automated discovery pipelines used in drug development and personalized medicine, reducing false positives and accelerating scientific insight.

## Original Paper Reference
- **Source**: [Original Paper](http://arxiv.org/abs/2608.11156v1)
